FDA defers Omnitrope decision
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA notifies Sandoz Aug. 31 that "the agency is unable to reach a decision on whether to approve" the firm's recombinant human growth hormone Omnitrope. Sandoz is presenting the decision essentially as a tentative approval for the follow-on biologic to Pfizer's Genotropin. "According to the FDA letter…the agency has completed its review of Omnitrope and did not identify any deficiencies in the application," Sandoz says. However, FDA could not reach a final decision "due to uncertainty regarding scientific and legal issues." Sandoz acknowledges that approval of most follow-on biologics will require new legislation. Pfizer previously petitioned FDA not to approve the Omnitrope 505(b)(2) NDA on the grounds that it improperly relies on proprietary information...
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.